As CFRD is less common compared to the more frequent type 1 or type 2 diabetes, other measures of ß-cell function (e.g. C-peptide) or calculation of indices for insulin secretion and sensitivity might be practicable in clinical settings that may result in better assessment of glucose tolerance in CF patients. The gene discussed is INS; the disease is cystic fibrosis.